FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * Davis Chaim 2. Issuer Name and Ticker or Trading Symbol AMERICAN BIO MEDICA CORP [ abmc ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)__X__ Director                    __X__ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)         (First)         (Middle)
C/O ABMC, 122 SMITH ROAD
3. Date of Earliest Transaction (MM/DD/YYYY)
3/2/2020
(Street)
KINDERHOOK, NY 12106
(City)       (State)       (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)
 
6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Shares  3/2/2020    P    528571 (1) A $0.07 (2) 2978486  I (3) By Revach Fund, LP 

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:
(1)  These restricted common shares were issued on 3/2/20 in connection with a private placement dated 2/20/20. The Revach Fund, LP was one of the accredited investors who participated in the private placement. 528,571 units were purchased at $0.07 per share; resulting in a total purchase price of $37,000. Davis is a managing member of Revach Group, LLC which operates as the general partner for Revach Fund, LP. Davis serves as the Chairman of the Board of American Bio Medica Corporation.
(2)  The price per unit in the private placement was $0.07.
(3)  The common shares are in the name of Revach Fund, LP. The reporting person (Davis) is a managing member of Revach Group, LLC which operates as the general partner for Revach Fund, LP.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Davis Chaim
C/O ABMC
122 SMITH ROAD
KINDERHOOK, NY 12106
X X


Signatures
Chaim Davis 3/3/2020
**Signature of Reporting Person Date
American Bio Medica (PK) (USOTC:ABMC)
Historical Stock Chart
From Aug 2020 to Sep 2020 Click Here for more American Bio Medica (PK) Charts.
American Bio Medica (PK) (USOTC:ABMC)
Historical Stock Chart
From Sep 2019 to Sep 2020 Click Here for more American Bio Medica (PK) Charts.